BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27683844)

  • 1. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.
    Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK
    Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalent antiepileptic drug switching and the risk of seizure-related events.
    Hansen RN; Nguyen HP; Sullivan SD
    Epilepsy Res; 2013 Sep; 106(1-2):237-43. PubMed ID: 23726541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refilling and switching of antiepileptic drugs and seizure-related events.
    Gagne JJ; Avorn J; Shrank WH; Schneeweiss S
    Clin Pharmacol Ther; 2010 Sep; 88(3):347-53. PubMed ID: 20631693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: A nationwide study of prescription data in Germany.
    Lang JD; Kostev K; Onugoren MD; Gollwitzer S; Graf W; Müller T; Olmes DG; Hamer HM
    Ann Neurol; 2018 Dec; 84(6):918-925. PubMed ID: 30298621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study.
    Polard E; Nowak E; Happe A; Biraben A; Oger E;
    Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1161-9. PubMed ID: 26395769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
    Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.
    Shcherbakova N; Rascati K; Brown C; Lawson K; Novak S; Richards KM; Yoder L
    CNS Drugs; 2014 Nov; 28(11):1047-58. PubMed ID: 25086640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
    Kwan P; Palmini A
    Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
    Das S; Jiang X; Jiang W; Ting TY; Polli JE
    Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
    Zachry WM; Doan QD; Clewell JD; Smith BJ
    Epilepsia; 2009 Mar; 50(3):493-500. PubMed ID: 18616554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F; Duh MS; Gosselin A; Paradis PE
    Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS
    Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
    Hartung DM; Middleton L; Svoboda L; McGregor JC
    CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: A US database analysis.
    Faught E; Helmers S; Thurman D; Kim H; Kalilani L
    Epilepsy Behav; 2018 Aug; 85():37-44. PubMed ID: 29906700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy.
    Das S; Pu X; Jiang X; Jiang W; Tung R; Ting TY; Polli JE
    Epilepsy Behav; 2019 Jan; 90():197-203. PubMed ID: 30579779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden associated with the use of generic antiepileptic drugs in the United States.
    Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM
    Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brand name to generic substitution of levetiracetam in patients with epilepsy.
    Gha-Hyun L; Dae SJ
    Seizure; 2018 Aug; 60():127-131. PubMed ID: 29960217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic antiepileptic drug prescribing: a cross-sectional study.
    Meyer J; Fardo D; Fleming ST; Hopenhayn C; Gokun Y; Ryan M
    Epilepsy Behav; 2013 Jan; 26(1):1-6. PubMed ID: 23182806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?
    Holtkamp M; Theodore WH
    Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic burden of breakthrough seizures.
    Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
    Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.